Allogene Therapeutics Inc. (ALLO), a clinical-stage biotechnology company, is scheduled to present new data from its ongoing phase I TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) on November 8, 2024.
TRAVERSE is an ongoing phase I trial designed to evaluate the safety, tolerability, and activity of ALLO-316 in patients with advanced or metastatic clear cell renal cell carcinoma.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.